DGIdb - MTOR Gene Record

MTOR 2475 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

2475
MECHANISTIC TARGET OF RAPAMYCIN KINASE
MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
SKS
601231
3942
ENSG00000198793
OTTHUMG00000002001
P42345
FRAP_HUMAN
MTOR_HUMAN
SERINE/THREONINE-PROTEIN KINASE MTOR
FKBP12-rapamycin complex-associated protein
Rapamycin and FKBP12 target 1
FK506-binding protein 12-rapamycin complex-associated protein 1
Rapamycin target protein 1
Mechanistic target of rapamycin
Mammalian target of rapamycin
FKBP12-RAPAMYCIN COMPLEX-ASSOCIATED PROTEIN (FK506-BINDING PROTEIN 12- RAPAMYCIN COMPLEX-ASSOCIATED PROTEIN 1) (RAPAMYCIN TARGET PROTEIN) (RAPT1) (MAMMALIAN TARGET OF RAPAMYCIN) (MTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P42345]
2073
PA28360
T75243

Gene Info:

Target Main Class	Enzymes
Target Subclass	2.7.11.1
CancerCommons Reported Gene Name	PI3K/mTOR
CancerCommons Reported Gene Name	mTOR
CancerCommons Reported Gene Name	TORC
Interpro Acc	IPR000403
Uniprot Evidence	1: Evidence at protein level
Human Readable Name	PHOSPHATIDYLINOSITOL 3 KINASE
Interpro Type	Domain
Interpro Name	Phosphatidylinositol 3-/4-kinase, catalytic domain
Uniprot Status	Swiss-Prot
Human Readable Name	DRUGGABLE GENOME
Interpro Short Name	PI3/4_kinase_cat_dom
Target Class	Enzymes
Target Subclass	EC:2.7.11.1
Gene Biotype	PROTEIN_CODING

(22 More Sources)

Gene Categories: Category Details

KINASE
SERINE THREONINE KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
PHOSPHATIDYLINOSITOL 3 KINASE
CLINICALLY ACTIONABLE
ENZYME

Publications:

Morales GA et al., 2013, Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors., J Med Chem
Venkatesan et al., 2010, Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor., J. Med. Chem.
Hong JY et al., 2011, Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa., J Nat Prod
Koh M et al., 2013, A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells., Bioorg Med Chem
Wong CP et al., 2015, Bisleuconothine A Induces Autophagosome Formation by Interfering with AKT-mTOR Signaling Pathway., J Nat Prod
Salomé C et al., 2014, Benzofuran derivatives as anticancer inhibitors of mTOR signaling., Eur J Med Chem
Voss et al., 2014, Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy., Clin. Cancer Res.
Wagle et al., 2014, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib., Cancer Discov
Lim et al., 2016, Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus., Oncotarget
Raushenbakh et al., 1976, [Induction of tyrosine aminotransferase by blastomogenic metabolites of tryptophan and tyrosine]., Biull Eksp Biol Med
Silen et al., 1975, Acid-base balance in amphibian gastric mucosa., Am. J. Physiol.
Wagle et al., 2014, Response and acquired resistance to everolimus in anaplastic thyroid cancer., N. Engl. J. Med.
Ettenger et al., 2008, Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year., Pediatr Transplant
Teachey et al., 2009, Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies., Br. J. Haematol.
Coppin, 2010, Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib., Biologics
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
George et al., 2009, Role of everolimus in the treatment of renal cell carcinoma., Ther Clin Risk Manag
Rostaing et al., mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?, J. Nephrol.
Albert et al., 2010, New inhibitors of the mammalian target of rapamycin signaling pathway for cancer., Expert Opin Investig Drugs
Stjepanovic N et al., 2015, Elucidating the genomic landscape of breast cancer: how will this affect treatment?, Pharmacogenomics
Patard et al., 2008, Targeted therapy in renal cell carcinoma., World J Urol
Radulovic et al., 2007, Sunitinib, sorafenib and mTOR inhibitors in renal cancer., J BUON
Reitamo et al., 2002, Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis., Am J Clin Dermatol
Li J et al., 2011, Mitochondrial respiration inhibitors suppress protein translation and hypoxic signaling via the hyperphosphorylation and inactivation of translation initiation factor eIF2α and elongation factor eEF2., J Nat Prod
Nowak P et al., 2009, Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase., J Med Chem
Pratt MR et al., 2007, Small-molecule-mediated rescue of protein function by an inducible proteolytic shunt., Proc Natl Acad Sci U S A
Du L et al., 2014, Cytotoxic dimeric epipolythiodiketopiperazines from the ascomycetous fungus Preussia typharum., J Nat Prod
Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
Grabiner et al., 2014, A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity., Cancer Discov
Rodrik-Outmezguine et al., 2016, Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor., Nature
Shuuin et al., 2009, [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma]., Gan To Kagaku Ryoho
Sehgal, 2003, Sirolimus: its discovery, biological properties, and mechanism of action., Transplant. Proc.
Dowling et al., 2010, Dissecting the role of mTOR: lessons from mTOR inhibitors., Biochim. Biophys. Acta
Xu et al., 2016, Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin., J. Clin. Invest.
Palanki et al., 2007, Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction., J. Med. Chem.
Ballou et al., 2007, Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one., J. Biol. Chem.
Pike et al., 2013, Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014., Bioorg. Med. Chem. Lett.
Cavell BE et al., 2012, Natural product-derived antitumor compound phenethyl isothiocyanate inhibits mTORC1 activity via TSC2., J Nat Prod
Kong et al., 2016, Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors., Clin. Cancer Res.

DS-3078A MTOR

Interaction Score: 0.97

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

Reported Cancer Type Lung

PMIDs:
None found

Sources:
ChemblInteractions CancerCommons
BISLEUCONOTHINE A MTOR

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26176165

Sources:
DTC
RG-7603 MTOR

Interaction Score: 0.97

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

PMIDs:
None found

Sources:
ChemblInteractions TTD
RIDAFOROLIMUS MTOR

Interaction Score: 0.97

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Trial Name Ridaforolimus

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD
CHEMBL582278 MTOR

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL597874 MTOR

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL568150 MTOR

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AZD-2014 MTOR

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CHEMBL578420 MTOR

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALOMID-529 MTOR

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ZOTAROLIMUS MTOR

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CHEMBL2348411 MTOR

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23490148

Sources:
DTC
TEMSIROLIMUS MTOR

Interaction Score: 0.39

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Lung

Trial Name temsirolimus, CCI-779,Torisel

PMIDs:
18265991 11752352 17935273

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB
CC-223 MTOR

Interaction Score: 0.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

Reported Cancer Type Lung

PMIDs:
None found

Sources:
ChemblInteractions CancerCommons TTD
EVEROLIMUS MTOR

Interaction Score: 0.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status case report

PMIDs:
26176165 24836070 24622468 24625776 26859683 11010 2015 25295501 18466433 19344392 20531964 11752352 19774211 20155724 20569080 25893859

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND DoCM CIViC MyCancerGenomeClinicalTrial PharmGKB TTD OncoKB
BGT-226 MTOR

Interaction Score: 0.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC TTD
PIMECROLIMUS MTOR

Interaction Score: 0.32

Interaction Types & Directionality:

potentiator

Interaction Info:

Trial Name pimecrolimus, ASM 981,Elidel

Novel drug target Established target

PMIDs:
12113647

Sources:
TdgClinicalTrial
TRIFLUPERIDOL MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
EBASTINE MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1255834 MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
BUTACLAMOL MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PWT-33579 MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CC-115 MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CHEMBL605077 MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL599088 MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IFENPRODIL MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL195350 MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GLASDEGIB MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
TG100-115 MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17685602

Sources:
DTC
CHEMBL303958 MTOR

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OSI-027 MTOR

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Trial Name OSI-027

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions TTD
YUANHUADINE MTOR

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21916433

Sources:
DTC
SIROLIMUS MTOR

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name LCP-Siro, sirolimus

Novel drug target Established target

Trial Name sirolimus, rapamycin,Perceiva

PMIDs:
19848404 24836070 17563385 24893224 26619011 24631838 27279227 19620795 12742462 11752352 20005306 27482884

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial DoCM CIViC TTD
CHEMBL528712 MTOR

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ZOLANTIDINE MTOR

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL528807 MTOR

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL600334 MTOR

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISTIRATUMAB MTOR

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CHEMBL527620 MTOR

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
BIMIRALISIB MTOR

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
AZD-8055 MTOR

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

PMIDs:
23375793

Sources:
DTC MyCancerGenome ChemblInteractions
PHENETHYLISOTHIOCYANATE MTOR

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22607231

Sources:
DTC
PKI-179 MTOR

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
THAPSIGARGIN MTOR

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CANTHARIDIC_ACID MTOR

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PF-04691502 MTOR

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions TTD
CAPIVASERTIB MTOR

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26490311

Sources:
CIViC
LY-294002 MTOR

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17562705

Sources:
DTC
VOXTALISIB MTOR

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

Reported Cancer Type Melanoma

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions CancerCommons TTD
GEDATOLISIB MTOR

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

PMIDs:
20166697

Sources:
DTC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial TTD
EMETINE MTOR

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DOXAZOSIN MTOR

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL591618 MTOR

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL587620 MTOR

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SAMOTOLISIB MTOR

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
PENTAMIDINE ISETHIONATE MTOR

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VS-5584 MTOR

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
CHEMBL569864 MTOR

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DS-7423 MTOR

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
IDAZOXAN MTOR

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB MTOR

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
23410005

Sources:
DTC MyCancerGenome ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial TTD
CANERTINIB MTOR

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL596380 MTOR

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CGS-15943 MTOR

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL602127 MTOR

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ROTENONE MTOR

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21875114

Sources:
DTC
SAPANISERTIB MTOR

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions TTD
DIPHENYLENEIODONIUM MTOR

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL445102 MTOR

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PROPAFENONE MTOR

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VISTUSERTIB MTOR

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
RITANSERIN MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MIBEFRADIL MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SF-1126 MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PWT-33587 MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BGT-226 MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SALIRASIB MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
BERZOSERTIB MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
QUINACRINE MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SU-9516 MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LESTAURTINIB MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LOPERAMIDE MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
APITOLISIB MTOR

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
MAPROTILINE MTOR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
(R,S)-INDATRALINE MTOR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DEQUALINIUM MTOR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TANESPIMYCIN MTOR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PANULISIB MTOR

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
CHEMBL601364 MTOR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PYRROLIDINE DITHIOCARBAMATE MTOR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TERFENADINE MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
NICARDIPINE MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CAFFEIC ACID PHENETHYL ESTER MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL24983 MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AMSACRINE MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PERPHENAZINE MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OLEOYL DOPAMINE MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
WIN-552122 MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MIFEPRISTONE MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CALCIMYCIN MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMIPALISIB MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
VANOXERINE MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PI-103 MTOR

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PHENANTHROLINE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GR-127935 MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAZOPANIB MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24625776

Sources:
CIViC
AMIODARONE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TYRPHOSTIN A9 MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CATECHOL MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
INFIGRATINIB MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PAROXETINE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PIMOZIDE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FENRETINIDE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
NICLOSAMIDE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METFORMIN HYDROCHLORIDE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23490148

Sources:
DTC
ISOPROTERENOL MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
EPINEPHRINE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ALPELISIB MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Lung

PMIDs:
None found

Sources:
CancerCommons
CAMPTOTHECIN MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IDARUBICIN MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METFORMIN MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
DISULFIRAM MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GOSSYPOL MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL429095 MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ME-344 MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
VANDETANIB MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HALOPERIDOL MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

Ensembl: ENSG00000198793
- Version: 101_38
Alternate Names:

MTOR Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

RussLampel: ENSG00000198793

Version: 26-July-2011

Alternate Names:

ENSG00000198793 Ensembl Gene Id

FKBP12-RAPAMYCIN COMPLEX-ASSOCIATED PROTEIN (FK506-BINDING PROTEIN 12- RAPAMYCIN COMPLEX-ASSOCIATED PROTEIN 1) (RAPAMYCIN TARGET PROTEIN) (RAPT1) (MAMMALIAN TARGET OF RAPAMYCIN) (MTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P42345] Description

FRAP1 Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TEND: P42345
- Version: 01-August-2011
Alternate Names:

2475 Entrez Gene Id

FRAP_HUMAN Uniprot Id

FRAP1 Gene Symbol

Gene Info:

Target Main Class Enzymes

Target Subclass 2.7.11.1

Publications:
TdgClinicalTrial: P42345
- Version: January-2014
Alternate Names:

MTOR Gene Symbol

FRAP1 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:2.7.11.1

Publications:
CancerCommons: MTOR
- Version: 25-July-2013
Alternate Names:

2475 Entrez Gene ID

Gene Info:

CancerCommons Reported Gene Name PI3K/mTOR

CancerCommons Reported Gene Name mTOR

CancerCommons Reported Gene Name TORC

Publications:
HopkinsGroom: P42345
- Version: 11-September-2012
Alternate Names:

P42345 Uniprot Accession

2475 Entrez Gene Id

ENSG00000198793 Ensembl Gene Id

Gene Info:

Interpro Acc IPR000403

Uniprot Evidence 1: Evidence at protein level

Human Readable Name PHOSPHATIDYLINOSITOL 3 KINASE

Gene Categories:

DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE

Publications:
PharmGKB: MTOR
- Version: 18-August-2020
Alternate Names:

PA28360 PharmGKB ID

Gene Info:

Publications:

Stjepanovic N et al., 2015, Elucidating the genomic landscape of breast cancer: how will this affect treatment?, Pharmacogenomics

CIViC: MTOR

Version: 14-September-2020

Alternate Names:

2475 Entrez Gene ID

2073 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Wagle et al., 2014, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib., Cancer Discov

Wagle et al., 2014, Response and acquired resistance to everolimus in anaplastic thyroid cancer., N. Engl. J. Med.

Kong et al., 2016, Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors., Clin. Cancer Res.

TTD: Serine/threonine-protein kinase mTOR
- Version: 2020.06.01
Alternate Names:

mTOR TTD Gene Abbreviation

T75243 TTD Target ID

Gene Info:

Publications:

Janku F et al., 2013, PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials., Cancer Res

DoCM: MTOR

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.

Grabiner et al., 2014, A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity., Cancer Discov

Wagle et al., 2014, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib., Cancer Discov

DTC: MTOR

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Venkatesan et al., 2010, Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor., J. Med. Chem.

Nowak P et al., 2009, Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase., J Med Chem

Pratt MR et al., 2007, Small-molecule-mediated rescue of protein function by an inducible proteolytic shunt., Proc Natl Acad Sci U S A

MyCancerGenome: MTOR
- Version: 20-Jun-2017
Alternate Names:

2475 Entrez Gene Id

MTOR MyCancerGenome Gene Symbol

mTOR MyCancerGenome Reported Gene Name

Gene Info:

Publications:
HingoraniCasas: ENSG00000198793
- Version: 31-May-2017
Alternate Names:

ENSG00000198793 Gene Symbol

MTOR Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: FRAP
- Version: chembl_23
Alternate Names:

FRAP1 GENE_SYMBOL

FRAP2 GENE_SYMBOL

RAFT1 GENE_SYMBOL

Gene Info:

Publications:
TALC: MTOR
- Version: 12-May-2016
Alternate Names:

MTOR Gene Symbol

Gene Info:

Publications:
OncoKB: MTOR
- Version: 23-July-2020
Alternate Names:

2475 OncoKB Entrez Id

FRAP1 OncoKB Gene Synonym

RAFT1 OncoKB Gene Synonym

Gene Info:

Publications:
GO: MTOR
- Version: 01-February-2022
Alternate Names:

FRAP GO Gene Synonym

FRAP1 GO Gene Synonym

FRAP2 GO Gene Synonym

Gene Info:

Gene Categories:

KINASE, SERINE THREONINE KINASE

Publications:
Tempus: MTOR
- Version: 11-November-2018
Alternate Names:

MTOR Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: MTOR
- Version: 27-Jun-2013
Alternate Names:

2475 Gene ID

FRAP dGene Synonym

FRAP1 dGene Synonym

Gene Info:

Gene Categories:

KINASE, SERINE THREONINE KINASE

Publications:
Pharos: MTOR
- Version: 01-February-2022
Alternate Names:

Serine/threonine-protein kinase mTOR Gene Name

P42345 UniProt ID

Gene Info:

Gene Categories:

KINASE, ENZYME

Publications:
ClearityFoundationClinicalTrial: MTOR
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
MskImpact: MTOR
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MyCancerGenomeClinicalTrial: MTOR
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: MTOR
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: MTOR
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: MTOR
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Mechanism of Interaction	Serine/threonine-protein kinase mTOR inhibitor
Direct Interaction	yes
Reported Cancer Type	Lung

Notes
Reported Cancer Type	Lung
Trial Name	temsirolimus, CCI-779,Torisel

Variant Effect	gain-of-function
Pathway	activation
Clinical Status	case report

Trial Name	pimecrolimus, ASM 981,Elidel
Novel drug target	Established target

Trial Name	LCP-Siro, sirolimus
Novel drug target	Established target
Trial Name	sirolimus, rapamycin,Perceiva

Reported Cancer Type	Melanoma
Mechanism of Interaction	Serine/threonine-protein kinase mTOR inhibitor
Direct Interaction	yes

ENSG00000198793	Ensembl Gene Id
FKBP12-RAPAMYCIN COMPLEX-ASSOCIATED PROTEIN (FK506-BINDING PROTEIN 12- RAPAMYCIN COMPLEX-ASSOCIATED PROTEIN 1) (RAPAMYCIN TARGET PROTEIN) (RAPT1) (MAMMALIAN TARGET OF RAPAMYCIN) (MTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P42345]	Description
FRAP1	Display Id

P42345	Uniprot Accession
2475	Entrez Gene Id
ENSG00000198793	Ensembl Gene Id

2475	OncoKB Entrez Id
FRAP1	OncoKB Gene Synonym
RAFT1	OncoKB Gene Synonym

Serine/threonine-protein kinase mTOR	Gene Name
P42345	UniProt ID

MTOR Gene Record

MTOR 2475 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor Direct Interaction yes Reported Cancer Type Lung

PMIDs: None found

Sources: ChemblInteractions CancerCommons

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26176165

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor Trial Name Ridaforolimus

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23490148

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Reported Cancer Type Lung Trial Name temsirolimus, CCI-779,Torisel

PMIDs: 18265991 11752352 17935273

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor Direct Interaction yes Reported Cancer Type Lung

PMIDs: None found

Sources: ChemblInteractions CancerCommons TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Variant Effect gain-of-function Pathway activation Clinical Status case report

PMIDs: 26176165 24836070 24622468 24625776 26859683 11010 2015 25295501 18466433 19344392 20531964 11752352 19774211 20155724 20569080 25893859

Sources: TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND DoCM CIViC MyCancerGenomeClinicalTrial PharmGKB TTD OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC TTD

Interaction Types & Directionality: potentiator

Interaction Info: Trial Name pimecrolimus, ASM 981,Elidel Novel drug target Established target

PMIDs: 12113647

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

Reported Cancer Type Lung

PMIDs:
None found

Sources:
ChemblInteractions CancerCommons

Interaction Types & Directionality:

n/a

PMIDs:
26176165

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Trial Name Ridaforolimus

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
23490148

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Lung

Trial Name temsirolimus, CCI-779,Torisel

PMIDs:
18265991 11752352 17935273

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

Reported Cancer Type Lung

PMIDs:
None found

Sources:
ChemblInteractions CancerCommons TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status case report

PMIDs:
26176165 24836070 24622468 24625776 26859683 11010 2015 25295501 18466433 19344392 20531964 11752352 19774211 20155724 20569080 25893859

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND DoCM CIViC MyCancerGenomeClinicalTrial PharmGKB TTD OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC TTD

Interaction Types & Directionality:

potentiator

Interaction Info:

Trial Name pimecrolimus, ASM 981,Elidel

Novel drug target Established target

PMIDs:
12113647

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
None found